00:00Mines Biomed, a molecular genetics diagnostic company specializing in the early detection
00:06of cancer, today announced a collaborative agreement with Thermo Fisher Scientific Inc.
00:10NYSE, TMO, through its subsidiary Life Technologies Corporation. Thermo Fisher is
00:15a world leader in supplying life sciences solutions and services with annual revenue
00:20of over 40 billion dollars, marking a major milestone for Mines Biomed.
00:24The collaboration agreement will enable Mines Biomed and Thermo Fisher to jointly develop
00:28and potentially commercialize Mines Biomed's next-generation colorectal cancer screening
00:32product. The collaboration will harness Thermo Fisher's powerful technologies,
00:36instrumentation, and information translation systems to enable Mines Biomed to develop
00:40the proprietary assays for its mRNA-based next-generation CRC screening tests,
00:44which are redefining standards in early cancer detection.
00:47Mines Biomed's flagship non-invasive test not only targets the early detection of colorectal cancer,
00:52but also focuses on precancerous lesions, particularly advanced adenomas,
00:56demonstrating significant clinical success in both U.S. and European trials.
01:00The collaboration will leverage combined capabilities to deliver testing solutions
01:04being developed at Mines Biomed's laboratories in Mainz, Germany.
01:07Guido Baechler, CEO of Mines Biomed, said,
01:10This collaboration with Thermo Fisher will be instrumental to our goal to bring to market a
01:14home-collection colorectal screening tool with highly effective detection of adenomas.
01:19Our product development will be greatly enhanced by Thermo Fisher's knowledge
01:22and scalable, class-leading technologies, providing both partners with a means to
01:26accelerate the availability of an innovative new test for colorectal cancer screening around the world.
01:30Peter Jacobs, Director, EMEA Clinical Business Development, Thermo Fisher Scientific, said,
01:36We are excited at the prospect of working with Mines Biomed on their next-generation screening
01:40test and are confident that together we will be able to achieve rapid progress
01:44and deliver innovative new assays for the global clinical marketplace.
Comments